{"filings":[{"id":1304328,"accession_number":"0001193125-26-285498","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2026-06-26T20:15:14+00:00","items":["5.02"],"status":"ready","headline":"Atara CAO to depart July 17; Kevin Sarney appointed interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Yanina Grant-Huerta, Chief Accounting Officer, notified on June 22 that employment ends July 17, 2026.","Board appointed Kevin G. Sarney (CRCFO) as interim CFO effective June 26; he serves as principal financial and accounting officer.","Sarney has over 25 years life science finance experience, previously at PwC and executive roles at public/private life science companies.","Sarney paid through CRCFO consulting; company pays hourly rate; no direct compensation from company.","Consulting agreement terminable on 30 days notice; Sarney enters standard indemnification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1027331,"accession_number":"0001213900-26-068264","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2026-06-12T20:05:45+00:00","items":["5.02","5.07"],"status":"ready","headline":"Atara appoints Brian Cherry to board; annual meeting votes approve equity plan amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Brian Cherry appointed as Class I director, effective June 11, 2026; also joins Audit Committee.","Initial RSU award of 24,000 shares vesting over 3 years; annual cash retainer $55,000.","Stockholders elected AnhCo Nguyen and Nachi Subramanian to board at June 9 annual meeting.","Advisory say-on-pay and amendment to 2024 Equity Incentive Plan (+400,000 shares) approved.","Deloitte & Touche ratified as independent auditor for fiscal year ending December 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":40405,"accession_number":"0001193125-26-219420","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2026-05-12T20:10:15+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q1 2026 net loss $4.1M; cash runway extended; FDA agrees path for tab-cel BLA resubmission","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.1M ($0.29 diluted EPS) vs net income $38.0M ($3.50 diluted) in Q1 2025.","Revenue $0.5M (prior Q1: $98.1M) due to FY2025 one-time tab-cel manufacturing transfer revenue.","Cash $8.4M at Mar 31; plus $4.8M ATM proceeds post-quarter; runway into mid-2027.","FDA agreed single-arm ALLELE study with historical control could support tab-cel BLA resubmission; update expected Q3 2026.","R&D expenses $0.2M (vs $27.4M), G&A $3.6M (vs $11.5M) reflecting cost reductions."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":516000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94030,"accession_number":"0001193125-26-210413","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Atara biotherapeutics gets FDA alignment on tab-cel BLA resubmission path","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Type A meeting with FDA was productive; FDA agreed single-arm study with historical control could support future application.","Pierre Fabre to submit updated ALLELE study dataset with more patients and longer follow-up as part of resubmission.","Tabelecleucel is for R/R EBV+ PTLD post solid organ or hematopoietic cell transplant.","Company expects to provide further regulatory update in Q3 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94029,"accession_number":"0001193125-26-201397","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Atara Biotherapeutics receives Nasdaq delisting notice for market value deficiency","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Atara on April 30, 2026, that its MVLS fell below $50M for 30 consecutive business days.","Company has 180 calendar days, until October 27, 2026, to regain compliance by closing at $50M+ for 10+ consecutive days.","Stock continues trading on Nasdaq Global Select under ticker ATRA; company may consider transfer to Nasdaq Capital Market.","If not compliant by deadline, Nasdaq will provide delisting notice; Atara may appeal to a Hearings Panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106096,"accession_number":"0001193125-26-108344","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atara reports FY 2025 net income of $32.7M; cash runway extended through YE 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $32.7M ($2.61 per share) in FY 2025 vs. net loss of $85.4M in FY 2024.","Cash, equivalents and investments $8.5M at Dec 31, 2025; net cash used in ops $50.9M in FY 2025.","Operating expenses declined sharply; expects cash plus $3.0M ATM proceeds to fund ops through YE 2026.","Pierr Fabre scheduled FDA Type A meeting for tab-cel PTLD; regulatory update expected in Q2 2026.","Milestone payment of $9.0M due to HCRx deferred from June 2026 to Jan 2028; warrant issued for 400K shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106095,"accession_number":"0001193125-26-103127","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Atara announces FDA Type A meeting to discuss tabelecleucel BLA resubmission","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Type A meeting with FDA scheduled to discuss Complete Response Letter from Jan 9, 2026.","Partner Pierre Fabre to lead the meeting with Atara's support.","Goal: collaboratively address CRL points for resubmission using additional efficacy data.","Regulatory update expected in Q2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106094,"accession_number":"0001193125-26-086793","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Atara and Pierre Fabre request FDA Type A meeting for tabelecleucel BLA resubmission","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Pierre Fabre submitted Type A meeting request to FDA to address CRL issues for tabelecleucel (EBVALLO) BLA.","Briefing book argues ALLELE study was adequate; includes updated efficacy data and European post-marketing data.","FDA Complete Response Letter was issued January 9, 2026; meeting seeks path forward for EBV+ PTLD therapy.","CEO Cokey Nguyen cites urgent unmet need expressed by PTLD community and physician advocates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106093,"accession_number":"0001193125-26-062534","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Atara defers $9M milestone payment to HCRx to Jan 2028; issues 400K share warrant","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["HCRx agreed to extend $9.0M milestone payment due from June 30, 2026 to Jan 1, 2028.","Atara issued warrant to purchase 400K shares at $0.0001/share, exercisable immediately, no expiration.","CEO cites flexibility to address FDA Complete Response Letter (CRL) for tabelecleucel.","Tabelecleucel is approved in Europe for EBV+ PTLD; working with FDA for US path.","Warrant subject to 4.99% beneficial ownership limit; net number via cashless exercise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106092,"accession_number":"0001193125-26-010342","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"FDA issues CRL for Atara's EBVALLO BLA, reversing prior stance on trial adequacy","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA CRL received Jan 9, 2026; confirms GMP issues resolved but claims ALLELE trial inadequate for accelerated approval.","Atara and partner Pierre Fabre plan to request Type A meeting within 45 days to seek path forward.","Cash, cash equivalents and short-term investments as of Dec 31, 2025: approximately $8.5M.","Atara implemented ~90% headcount reduction and reduced ARC lease liability by ~65% in 2025.","Amendment to PFM agreement: approval milestone reduced to $31M, with potential $15M commercial milestone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106091,"accession_number":"0001193125-26-000907","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Atara amends Pierre Fabre deal: cuts regulatory milestones by $9M, adds $15M commercial milestone","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Regulatory milestone payments from Pierre Fabre reduced from $40M to $31M (decrease of $9M).","New $15M commercial milestone payable upon Product Net Sales exceeding a confidential threshold.","Amendment also modifies other payment sections (redacted) in the commercialization agreement.","Atara submitted BLA for tab-cel (EBV+ PTLD) to FDA in May 2024; Pierre Fabre has exclusive U.S. commercialization rights.","Agreement originally dated October 2023; fourth amendment effective December 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122386,"accession_number":"0001193125-25-276209","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atara Q3 net loss $4.3M; cash $13.7M; tab-cel BLA PDUFA Jan 10, 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $13.7M as of Sep 30, 2025, down from $22.3M at Jun 30.","Net loss of $4.3M ($0.32 per share) vs. $21.9M loss a year ago.","Total revenues $3.5M, down from $40.2M in Q3 2024 due to deferred revenue recognition.","Workforce reduced ~29% in Oct 2025; ~15 employees now retained.","FDA accepted tab-cel BLA with Priority Review; $40M milestone due from Pierre Fabre upon approval."],"consensus_eps_estimate":-0.8772,"consensus_eps_actual":2.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":119177000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122385,"accession_number":"0001193125-25-232117","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Atara Biotherapeutics cuts ~29% of workforce, retains ~15 employees","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction impacts about 29% of current employees; expects to complete by January 2026.","Approximately $1.3 million in severance and related benefits anticipated.","Roughly 50% of charges are salary continuation and 60-day notice wages under California WARN Act.","Company retains about 15 employees for strategic priorities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139094,"accession_number":"0000950170-25-112898","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Three directors resign from Atara Biotherapeutics board; Ciongoli named Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Directors Ameet Mallik, Pascal Touchon, and Maria Grazia Roncarolo resigned voluntarily effective Sept 2, 2025.","Board size reduced from 10 to 7 directors as of the same date.","Gregory A. Ciongoli appointed as Chair to succeed Pascal Touchon."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139093,"accession_number":"0000950170-25-106533","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atara Q2 net income $2.4M; tab-cel BLA accepted with Jan 10, 2026 PDUFA date","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and short-term investments $22.3M at June 30, up from $13.8M at March 31.","Net income $2.4M ($0.19 diluted EPS) vs. net loss prior year; revenues $17.6M, down from $28.6M.","FDA accepted tab-cel BLA with Priority Review; PDUFA goal date January 10, 2026.","Completed transfer of substantially all tab-cel activities to Pierre Fabre; $40M milestone due on FDA approval.","Full-year 2025 operating expenses expected to decrease at least 60% vs 2024; strategic options evaluation resumed."],"consensus_eps_estimate":-0.4692,"consensus_eps_actual":3.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":115724000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139092,"accession_number":"0001193125-25-158719","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Atara resubmits tab-cel BLA to FDA for EBV+ PTLD; cash ~$22M, runway into Q1 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Atara resubmitted BLA to FDA for tabelecleucel (tab-cel) for EBV+ PTLD after CRL related to manufacturing observations.","Pivotal ALLELE study showed 48.8% ORR (p<0.0001); no FDA-approved therapies in this setting.","Cash, cash equivalents and short-term investments ~$22M as of June 30, 2025; cost cuts extend runway into Q1 2026.","$40M milestone payment from Pierre Fabre due upon FDA approval; plus double-digit tiered royalties on net sales.","Transitioning tab-cel clinical studies to Pierre Fabre; Atara maintains BLA sponsorship."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156604,"accession_number":"0001193125-25-139150","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Atara Biotherapeutics announces 2025 annual meeting results; all proposals approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected directors: AnhCo Nguyen (2.71M for), Matthew Fust (2.58M for), Gregory Ciongoli (2.99M for).","Advisory vote on executive compensation approved 2.98M for vs 43K against.","Frequency of say-on-pay set to one year (3.00M votes for one year).","Ratified Deloitte & Touche as auditor for FY2025 with 4.39M for, 69K against, 79K abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156603,"accession_number":"0001193125-25-121824","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Atara Biotherapeutics raises ~$16M in registered direct offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$16M from 834,237 shares at $6.61/share and pre-funded warrants for 1,587,108 shares at $6.6099.","Pre-funded warrants have exercise price $0.0001/share, exercisable immediately, no expiration.","Net proceeds to fund BLA approval activities for tab-cel and for working capital.","Underwriting agreement with TD Securities; offering expected to close May 16, 2025.","30-day lock-up on issuance and sale of company securities post-closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156602,"accession_number":"0001193125-25-120345","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Atara Q1 net income $38M; FDA lifts EBVALLO holds; $16M offering closes May 16","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $38.0M ($3.50 diluted EPS) vs net loss of $31.8M in Q1 2024; revenue $98.1M, up from $27.4M, driven by Pierre Fabre milestone.","Cash $13.8M at Mar 31, 2025; with $16M gross proceeds from May offering, expects runway into Q1 2026.","FDA lifted clinical holds on EBVALLO; Type A meeting Q2 2025 to address CRL; plans to resume Phase 3 ALLELE study.","Workforce reduced ~30% in May, retaining ~23 staff; FY2025 operating expenses expected to decrease ~65% YoY.","James Huang (Panacea) and Nachi Subramanian (Redmile) appointed to board effective after offering close."],"consensus_eps_estimate":null,"consensus_eps_actual":3.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":98149000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156601,"accession_number":"0000950170-25-069198","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Atara Biotherapeutics reduces workforce by ~30% to retain ~23 employees","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approximately 30% workforce reduction, retaining ~23 employees; expected completion by August 2025.","Expected severance and related costs of $1.4 million in one-time cash charges.","Additional details to be provided in the Q2 2025 10-Q filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156600,"accession_number":"0001193125-25-113811","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA lifts clinical hold on Atara's EBVALLO program; Type A meeting granted","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA lifted clinical hold on EBVALLO (tabelecleucel) IND applications, allowing resumption of Phase 3 ALLELE and Phase 2 label-expansion studies.","FDA granted a Type A meeting to discuss path forward for BLA resubmission after January 2025 CRL citing GMP issues at third-party facility.","Strategic option evaluation temporarily paused pending FDA clarity on BLA resubmission timing.","Clinical hold directly linked to GMP compliance issues identified during pre-license inspection; resolved with supplemental finished drug product data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156599,"accession_number":"0000950170-25-051121","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Atara amends Pierre Fabre deal; transfers manufacturing, reduces milestones; eligible for up to $550M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Transferred all manufacturing responsibility for tab-cel to Pierre Fabre as of March 31, 2025; Pierre Fabre will manufacture and supply worldwide at its cost.","Pierre Fabre assumes remediation costs for third-party facility to address FDA requests and support BLA resubmission for tab-cel.","Atara reduced certain potential future regulatory and commercial milestone payments in exchange for the accelerated transfer and cost assumption.","Atara now entitled to aggregate of up to $550M in potential milestones, including up to $40M regulatory milestones for FDA BLA approval; royalties unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175030,"accession_number":"0001193125-25-068789","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Atara CFO/COO Eric Hyllengren to depart March 31; Yanina Grant-Huerta named CAO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO/COO Eric Hyllengren's employment ends March 31, 2025; he will provide consulting through July 31 at an hourly rate.","Hyllengren receives severance including 2024 bonus; he relinquishes all vested and unvested stock option awards.","Yanina Grant-Huerta appointed Chief Accounting Officer and principal accounting officer effective March 31; she was VP of FP&A since March 2023.","Grant-Huerta previously spent 13 years at Amgen; no family relationships or related-party transactions disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175029,"accession_number":"0000950170-25-035482","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2025-03-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atara Q4 2024 net loss $12.7M; workforce cut 50%; pauses CAR-T programs; EBVALLO BLA resubmission ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.7M ($1.19/share) for Q4 2024 vs $60.5M loss in Q4 2023; full year loss $85.4M.","Cash and equivalents $42.5M at Dec 31, 2024; entered non-binding term sheet for up to $15M equity line with Redmile Group.","Workforce reduced ~50%, retaining ~35 personnel to focus on EBVALLO BLA resubmission and CAR-T wind-down.","Paused ATA3219 and ATA3431 CAR-T programs; discontinued Phase 1 NHL study for ATA3219.","FDA CRL in Jan 2025 cited third-party manufacturing issues; clinical hold on EBVALLO; regulatory update expected in Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175028,"accession_number":"0000950170-25-030832","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["2.05","9.01"],"status":"ready","headline":"Atara Biotherapeutics cuts 50% of workforce, discontinues two CAR T programs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reducing workforce by ~50%; expected to substantially complete by June 2025.","Discontinuing all development for ATA3219 and ATA3431, including CAR T clinical studies.","Estimated severance and related benefits of $3.0 million, primarily one-time cash charges.","Additional details to be provided in the Q1 2025 10-Q filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175027,"accession_number":"0000950170-25-009225","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2025-01-27T23:59:59+00:00","items":["2.05","9.01"],"status":"ready","headline":"Atara Biotherapeutics cuts workforce by ~50%; expects $7.5M severance costs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction impacts ~50% of current employees; completion expected by June 2025.","Estimated severance and related benefits of approximately $7.5 million, primarily one-time cash charges.","Additional details to be disclosed in Q1 2025 Form 10-Q.","Company may incur other charges not currently contemplated from the reduction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175026,"accession_number":"0000950170-25-006992","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Atara Biotherapeutics receives FDA clinical hold on EBVALLO and ATA3219 programs","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA clinical hold on EBVALLO and ATA3219 studies due to GMP compliance issues at third-party manufacturer.","New patient enrollment paused; currently enrolled patients who may benefit can continue treatment.","Clinical hold linked to inadequately addressed GMP issues from Jan 16 CRL for EBVALLO.","Atara's second manufacturer FDB in Thousand Oaks unaffected; remains part of long-term strategy.","FDA committed to working expeditiously with Atara to resolve clinical hold."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175025,"accession_number":"0000950170-25-006191","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Atara receives FDA Complete Response Letter for EBVALLO BLA due to third-party manufacturing issues","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA CRL solely related to third-party manufacturer inspection findings; no clinical efficacy/safety issues, no new trials requested.","Atara expects resubmission within 6 months after GMP compliance resolved; potential approval within 6 months of resubmission.","Preliminary cash and investments ~$43M as of Dec 31, 2024; non-binding term sheet with Redmile for up to $15M equity line.","Atara exploring strategic alternatives; may suspend CAR-T activities if no funding by Q1 2025; committed to preserving EBVALLO value.","Atara remains eligible for $60M milestone from Pierre Fabre upon FDA approval and double-digit royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191990,"accession_number":"0001193125-24-284167","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Atara Biotherapeutics adopts Third Amended and Restated Bylaws with governance changes","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved revised bylaws effective Dec 20, 2024; includes rights to postpone/cancel special stockholder meetings.","Grants Board exclusive use of white proxy card; enhances chair's authority over meeting conduct.","Tightens disclosure and procedural requirements for stockholder proposals and director nominations.","Adds severability clause and other administrative updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191989,"accession_number":"0000950170-24-125334","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Atara Q3 net loss narrows to $21.9M; tab-cel PDUFA Jan 15, 2025; CLO departs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.9M ($2.93/share) vs $69.8M ($16.40) YoY; revenue rose to $40.2M from $2.1M.","Cash, equivalents & investments $67.2M; net cash used in ops $4.0M vs $51.3M; cash runway into 2027.","Tab-cel BLA on track; PDUFA Jan 15, 2025; no advisory committee; potential $60M milestone from Pierre Fabre.","First patient dosed in ATA3219 NHL study; initial data Q1 2025. Lupus nephritis study start by year-end; data mid-2025.","Chief Legal Officer Amar Murugan departed Nov 8; consulting role at $250/hr; severance and bonuses tied to tab-cel milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":-11.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":96187000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191988,"accession_number":"0001193125-24-237582","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Atara Biotherapeutics appoints Eric Hyllengren as COO, retains CFO role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Hyllengren appointed Chief Operating Officer effective Oct 14, 2024, while continuing as CFO.","Salary increased to $520,000 per year in connection with the promotion.","Hyllengren has been CFO since April 2023 and with Atara since 2018."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208455,"accession_number":"0001193125-24-212168","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Atara raises ~$36M via registered direct offering; appoints Gregory Ciongoli to board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Registered direct offering of 758,900 shares and pre-funded warrants for up to 3,604,780 shares at $8.25/$8.2499.","Gross proceeds ~$36M; net proceeds for working capital and general corporate purposes.","Adiumentum Capital Fund I LP (Ciongoli is Managing Partner) purchases $7.5M of the offering.","Gregory A. Ciongoli appointed to Board of Directors effective upon closing on September 5, 2024.","Ciongoli is independent, not receiving director compensation; standard indemnification agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208454,"accession_number":"0000950170-24-095526","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Atara CEO Pascal Touchon to step down, succeeded by Cokey Nguyen; Q2 net loss narrows to $19M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pascal Touchon steps down as CEO effective Sep 9, 2024, becomes Chairman; Cokey Nguyen promoted to President and CEO.","Q2 2024 net loss of $19.0M ($3.10 per share) vs $71.1M loss in Q2 2023; revenue of $28.6M (up from $1.0M).","Tab-cel BLA accepted with Priority Review, PDUFA target Jan 15, 2025; $20M milestone received from Pierre Fabre.","Cash, equivalents, short-term investments $35.3M; with milestones and inventory purchase total liquidity $73.2M; cash runway into 2027.","ATA3219 NHL study enrolling with initial data expected Q1 2025; LN study initiation Q4 2024, data mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208453,"accession_number":"0001193125-24-180371","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Atara Biotherapeutics' tab-cel BLA accepted for priority review by FDA; PDUFA Jan 15, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["BLA for tabelecleucel (tab-cel) accepted for priority review to treat EBV+ PTLD in patients ≥2 years with ≥1 prior therapy.","PDUFA target action date set for January 15, 2025; no FDA-approved therapy currently exists for this indication.","BLA acceptance triggers $20M milestone payment from Pierre Fabre; up to $60M additional if FDA approves.","Supported by ALLELE study data showing 48.8% objective response rate (p<0.0001) and favorable safety profile.","Tab-cel already approved as Ebvallo in EU, UK, and Switzerland for relapsed/refractory EBV+ PTLD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226135,"accession_number":"0001193125-24-164554","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Atara Biotherapeutics effects 1:25 reverse stock split effective June 20, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio of 1:25 approved by board on June 10, effective June 20.","Common stock begins trading on split-adjusted basis under new CUSIP 046513206.","No fractional shares; cash payment based on closing price prior to effective date.","Stockholders approved proposal at annual meeting on June 10, 2024.","Amendment filed with Delaware Secretary of State."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226134,"accession_number":"0001193125-24-162069","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Atara Biotherapeutics announces 1-for-25 reverse stock split to comply with Nasdaq listing requirement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-25 ratio effective June 20, 2024 at 12:01 a.m. ET; post-split trading starts same day.","Outstanding shares reduced from ~122.6M to ~4.9M; fractional shares paid in cash.","Split authorized by stockholders on June 10, 2024; board set final ratio same day.","Purpose: regain compliance with Nasdaq $1.00 minimum bid price for continued listing.","Pre-funded warrants adjusted from 32.15M pre-split to ~1.29M post-split, subject to fractional cash payments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226133,"accession_number":"0001193125-24-158461","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Atara shareholders approve reverse stock split (1:4–1:30) and 2024 Equity Incentive Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split approved at board's discretion (ratio 1-for-4 to 1-for-30), board may abandon.","2024 Equity Incentive Plan approved: 53.96M for, 17.0M against, 24.84M broker non-votes.","Automatic annual increase to 2024 Equity Incentive Plan rejected: 26.63M for, 44.29M against.","Ratified Deloitte & Touche as auditors for FY2024: 89.69M for, 6.08M against.","Two directors elected: William K. Heiden and Ameet Mallik, each with >64M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226132,"accession_number":"0000950170-24-056901","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atara Q1 net loss narrows to $31.8M; tab-cel BLA on track for Q2 2024 submission","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 net loss of $31.8M ($0.23/sh) vs $74.8M ($0.72/sh) in Q1 2023; revenue rose to $27.4M from $1.2M on Pierre Fabre partnership.","Cash, equivalents, ST investments $46.2M plus AR $35.8M; expects funding into 2027 with potential $80M in tab-cel BLA milestones.","BLA submission for tab-cel in EBV+ PTLD planned Q2 2024; pivotal data showed 48.8% ORR (p<0.0001); Swissmedic approval received.","ATA3219 lupus nephritis study to start Q4 2024; initial data H1 2025; new SLE cohort without lymphodepletion also in Q4 2024.","Full-year 2024 operating expenses expected to decrease ~35% vs 2023; restructuring cut workforce by 25% to 170 employees."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":27357000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245216,"accession_number":"0000950170-24-038690","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Eric Dobmeier to not stand for re-election at Atara's 2024 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Dobmeier notified Atara on March 26, 2024, he will not stand for re-election at the 2024 annual meeting.","He will continue as director until his term expires at the 2024 Annual Meeting.","No disagreement with Board or management; decision not related to operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245215,"accession_number":"0000950170-24-037643","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atara posts Q4 loss $0.56/sh; tab-cel BLA submission on track for Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $60.5M ($0.56/diluted share); FY 2023 net loss $276.1M ($2.61/diluted share).","Cash, cash equivalents and short-term investments $51.7M at Dec 31, 2023; pro-forma ~$104M after Q1 2024 proceeds.","Tab-cel BLA submission on track for Q2 2024; $20M regulatory milestone expected in April 2024.","ATA3219 lupus nephritis Phase 1 to start H2 2024, initial data H1 2025; NHL study enrolling with data Q4 2024.","Two workforce reductions: ~30% in Nov 2023 and further ~25% in Jan 2024; headcount now ~170."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245214,"accession_number":"0000950170-24-019416","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2024-02-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Atara CMO Joshi departs; consulting deal includes $180K milestone on tabelecleucel BLA approval","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["EVP, Chief Medical Officer Dr. Joshi terminated Feb 2, 2024 as part of reduction in force.","Entered consulting agreement Feb 22, 2024: $3,000 monthly fee plus $300/hr for excess hours.","Outstanding RSU equity awards will continue vesting during consulting term.","Eligible for $180,000 payment upon FDA approval of tabelecleucel BLA.","Consulting arrangement runs through January 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245213,"accession_number":"0001193125-24-005188","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["1.01","3.01","9.01"],"status":"ready","headline":"Atara raises $15M via pre-funded warrants; Nasdaq warns of bid price deficiency","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$15M from sale of pre-funded warrants to purchase up to 27,272,727 shares at $0.55/warrant.","Warrants exercisable immediately at $0.0001/share, no expiration; proceeds for working capital and R&D.","Nasdaq notified ATRA that bid price closed below $1.00 for 30 consecutive days; 180-day cure period until July 8, 2024.","If not cured, company may transfer to Nasdaq Capital Market or effect reverse stock split; delisting possible.","Offering expected to close January 10, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245212,"accession_number":"0001193125-24-003945","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.05","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Atara cuts 25% of workforce, restructures to focus on CAR-T; CMO departs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~25% (approx. 56 employees) expected to complete by May 2024; severance costs ~$4.5M.","CMO Manher Joshi to depart Feb 2, 2024; receives 12 months severance, $3k/month consulting fee, $185k tab-cel BLA milestone.","Restructuring plus $27M upfront from Pierre Fabre pact and existing cash expected to fund operations into 2027.","Tab-cel BLA on track for Q2 2024 submission; pivotal ALLELE study showed ORR 49% (p<0.0001).","IND for ATA3219 in Lupus Nephritis planned Q1 2024; preliminary clinical data in lymphoma expected H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262664,"accession_number":"0000950170-23-071896","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2023-12-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Atara closes expanded tab-cel partnership with Pierre Fabre; receives ~$27M upfront, up to $640M total","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pierre Fabre gets development, manufacturing, commercialization rights for tab-cel in US and all remaining markets.","Atara receives ~$27M cash upfront and initial inventory purchase; potential milestones up to $640M total.","Potential $100M in regulatory milestones through BLA approval; significant double-digit tiered royalties on net sales.","Pierre Fabre to reimburse global development costs through BLA transfer; manufacturing transition planned at BLA transfer.","Atara plans to submit tab-cel BLA for PTLD to FDA in Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262663,"accession_number":"0001193125-23-273808","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Atara's Phase 2 ATA188 for non-active PMS misses primary endpoint; cash runway extended beyond Q3 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EMBOLD misses primary endpoint; treatment arm CDI 6% vs 33% in Phase 1; placebo rate 16% exceeded expected 4-6%.","No new safety signals observed; favorable safety profile for ATA188 in the study.","Company plans significant expense reductions on ATA188; focuses on allogeneic CAR-T pipeline; cash runway extended beyond Q3 2025.","Catalysts: ATA3431 preclinical data at ASH Dec 2023; Phase 1 data for ATA3219 in B-NHL expected H2 2024.","Tab-cel partnership with Pierre Fabre provides additional payments and significant double-digit royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262662,"accession_number":"0001193125-23-268185","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Atara Biotherapeutics establishes $100M ATM equity facility with TD Cowen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered into an at-the-market (ATM) sales agreement with TD Cowen for up to $100M in common stock.","Commission of up to 3.0% on gross proceeds; company controls timing and size of sales.","Replaces existing 2021 ATM facility once new shelf registration statement becomes effective.","No sales permitted until the registration statement is declared effective by the SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262661,"accession_number":"0000950170-23-057146","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["1.01","2.02","2.05","9.01"],"status":"ready","headline":"Atara expands tab-cel partnership worth up to $640M, cuts workforce 30%, Q3 loss $69.8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expanded global tab-cel deal with Pierre Fabre: up to $640M in payments, ~$30M upfront and $100M regulatory milestones, plus tiered double-digit royalties.","Workforce reduction of ~30% to extend cash runway into Q3 2025; $7M in severance charges expected.","Q3 net loss $69.8M ($0.66/sh) vs $84.1M ($0.82/sh) in prior year; cash, equivalents, and investments $102.4M at Sep 30.","ATA188 Phase 2 EMBOLD primary analysis on track for early Nov; focus shifts to ATA188 and AlloCAR-T programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279847,"accession_number":"0001193125-23-237762","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2023-09-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Atara announces FDA agreement on tab-cel comparability; BLA submission planned Q2 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA and Atara aligned on analytical comparability between manufacturing process versions of tab-cel.","Alignment allows pooling of pivotal clinical trial data from different process versions for BLA.","Atara expects to submit tab-cel BLA in Q2 2024, enabling inclusion of Phase 3 ALLELE data.","Company also advancing U.S. partnership discussions for tab-cel commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279846,"accession_number":"0000950170-23-039797","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atara Q2 net loss $71.1M; IND cleared for ATA3219; tab-cel BLA meeting scheduled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $71.1M ($0.68 per share) vs net income of $18.5M ($0.18) in Q2 2022, which included one-time gains.","Cash, equivalents and investments $153.6M as of June 30, 2023; expected runway into Q2 2024 (net cash used in ops $52.8M in Q2).","IND cleared for allogeneic CAR T ATA3219 in relapsed/refractory B-cell NHL; Phase 1 to start in coming months.","FDA meeting scheduled to resolve comparability for tab-cel (EBVALLO) BLA submission; commercial discussions advancing.","Primary analysis of ATA188 Phase 2 EMBOLD study in progressive MS to be communicated in early November with data from >90 patients."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":2183000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298306,"accession_number":"0000950170-23-027257","cik":1604464,"company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Atara CTO Charlene Banard departs; signs consulting deal through Sept 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Charlene Banard, EVP and Chief Technical Officer, left Atara on June 9, 2023.","She entered a consulting agreement with Atara from June 9 through September 30, 2023.","Consulting fee: $2,000 monthly for up to specified hours, plus $220/hr for excess hours.","Her outstanding equity awards will continue to vest during the consulting term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":94200445.37797914,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-06-09T23:59:59+00:00|298306"}